Page 107 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Alpha-2A receptor agonist and addiction

and other motivated individuals with OUDs. Despite its 4. Bolliger L, Stevens H. From opioid pain management
challenges with compliance, naltrexone offers sustained to opioid crisis in the USA: How can public-private
blockade of opioid receptors, mitigating the risk of partnerships help? Front Med (Lausanne). 2019;6:106.
overdose, intoxication, and subsequent re-addiction doi: 10.3389/fmed.2019.00106
in motivated patients. The development of clonidine 5. Srivastava AB, Mariani JJ, Levin FR. New directions
and naltrexone as treatment modalities for OUDs, as in the treatment of opioid withdrawal. Lancet.
well as other addictions, underscores the potential for 2020;395(10241):1938-1948.
translating neurobiological advancements from rodent
models (bench) to non-human primates and ultimately to doi: 10.1016/S0140-6736(20)30852-7
humans (bedside), leading to novel and efficacious clinical 6. Ziegenhorn AA, Roepke S, Schommer NC, et al. Clonidine
interventions (Table 1). improves hyperarousal in borderline personality disorder
with or without comorbid posttraumatic stress disorder:
Acknowledgments A randomized, double-blind, placebo-controlled trial. J Clin
Psychopharmacol. 2009;29(2):170-173.
The authors appreciate the expert edits of Margaret A.
Madigan. doi: 10.1097/JCP.0b013e31819a4bae
7. Gold MS, Pottash AC, Extein IL, Kleber HD. Neuroanatomical
Funding sites of action of clonidine in opioid withdrawal: The locus
The study is supported by The Pharmacotherapies for coeruleus connection. Prog Clin Biol Res. 1981;71:285-298.
Alcohol and Substance Abuse (PASA) Consortium (grant 8. Kane SP. Phar, BCPS. Clonidine. Available from: https://
no.: AS170014-A6). clincalc.com/drugstats/drugs/clonidine [Last accessed on
2023 Sep 22].
Conflict of interest 9. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline

®
Dr. Blum is the inventor of GARS and Pro-dopamine receptor agonists. Their pharmacology and therapeutic role.
Regulation (KB220Z™ ). There are no other conflicts of Anaesthesia. 1999;54(2):146-165.
interest. doi: 10.1046/j.1365-2044.1999.00659.xwsx
Author contributions 10. Foye WO. Foye’s Principles of Medicinal Chemistry.
Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
Conceptualization: All authors 11. Pajouhesh H, Lenz GR. Medicinal chemical properties
Writing – original draft: All authors of successful central nervous system drugs. NeuroRx.
Writing – review & drafting: All authors 2005;2(4):541-553.
Ethics approval and consent to participate doi: 10.1602/neurorx.2.4.541

Not applicable. 12. Fitzgerald PJ. Elevated norepinephrine may be a unifying
etiological factor in the abuse of a broad range of substances:
Consent for publication Alcohol, nicotine, marijuana, heroin, cocaine, and caffeine.
Subst Abuse. 2013;7:171-183.
Not applicable.
doi: 10.4137/SART.S13019
Availability of data 13. Glassman AH, Jackson WK, Walsh BT, Roose SP, Rosenfeld
Not applicable. B. Cigarette craving, smoking withdrawal, and clonidine.
Science. 1984;226(4676):864-866.
References doi: 10.1126/science.6387913
1. Neil MJ. Clonidine: Clinical pharmacology and 14. Giannini AJ, Extein I, Gold MS, Pottash AL, Castellani S.
therapeutic use in pain management. Curr Clin Pharmacol. Clonidine in mania. Drug Dev Res. 1983;3(1):101-103.
2011;6(4):280-287.
15. Streetz VN, Gildon BL, Thompson DF. Role of clonidine in
doi: 10.2174/157488411798375886 neonatal abstinence syndrome: A systematic review. Ann
Pharmacother. 2016;50(4):301-310.
2. Clonidine Monograph for Professionals. Available from:
https://www.drugs.com/monograph/clonidine.html [Last doi: 10.1177/1060028015626438
accessed on 2023 Sep 22].
16. Disher T, Gullickson C, Singh B, et al. Pharmacological
3. Yasaei R, Saadabadi A. Clonidine. Treasure Island, FL: treatments for neonatal abstinence syndrome: A systematic
StatPearls Publishing; 2023. review and network meta-analysis. JAMA Pediatr.

Volume 7 Issue 3 (2024) 13 doi: 10.36922/itps.1918